Leigh Felton B.Sc. Ph.D. is a Clinical Development Director at GlaxoSmithKline (GSK, Stevenage, UK) working within the late-stage Clinical Sciences Hepatology group.
He received his B.Sc. in Physiology and Pharmacology and Ph.D. in Psychoneuroimmunology from the University of Southampton, United Kingdom. He then went on to complete a postdoctoral research fellowship on the role of perturbations of the blood-brain-barrier in the immunopathology of Multiple Sclerosis.
Since joining GSK in 2006, Leigh has accrued 15 years’ experience of drug development over a broad range of therapeutic platforms, including small molecule inhibitors, biopharms, oligonucleotides and cell-based therapies. During this period he has worked extensively on Ph1-2b studies across multiple disease areas, including respiratory, autoimmune, oncology and infectious diseases. He has a strong background in clinical immunology and biomarker research, being recognised as a subject matter expert both within and outside of GSK, advising projects in preclinical development, early and late stage clinical development, and specialising in human challenge models and immune biomarker development. Leigh has been working on GSK’s Bepirovirsen (HBV ASO) project for functional cure of CHB infection for the past 3 years, and is currently clinical lead for sequenced therapy studies, including the B-Together Ph2b study (Bepirovirsen + Pegylated-IFN), and pediatric development activities.
